Mounjaro for weight loss patient criteria
WEIGHT LOSS MEDICATION (Mounjaro) is currently not available for NHS prescription at Watlington Medical Centre. Unfortunately we are not able to provide this service, as there is no capacity or funding for it, or any of the supportive wraparound care required to run alongside. This has not yet been commissioned by the ICB. We do not know when or if it will be resourced to provide.
You may have seen information in the media recently about the release of NICE guidance (TA1026) Mounjaro (Tirzepatide) injections for managing Obesity and Overweight in Adults, as well as its use to treat Type 2 Diabetes.
From 23rd June 2025 GPs will be able to prescribe Mounjaro on the NHS to certain cohorts of patients that meet strict eligibility criteria. NHS England have defined the first 3 cohorts of patients who will be able to access Mounjaro via their GP on the NHS. The cohorts have been decided nationally by NHS England, this is to prioritise treatment by clinical need.
Cohort 1: 23rd June 2025 A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. At least 4 of the following comorbidities:
• Hypertension and on treatment for blood pressure
• Dyslipidaemia (high cholesterol) or on cholesterol treatment “statins”
• Obstructive Sleep Apnoea
• Cardiovascular disease
• Type 2 diabetes
Cohort 2: June 2026 A BMI of 35 or higher, or 32.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. At least 4 of the following comorbidities:
• Hypertension and on treatment for blood pressure
• Dyslipidaemia (high cholesterol) or on cholesterol treatment “statins”
• Obstructive Sleep Apnoea
• Cardiovascular disease
• Type 2 diabetes
Cohort 3: April 2027 A BMI of 40 or higher, or 37.5 or higher if from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. At least 3 of the following comorbidities:
• Hypertension and on treatment for blood pressure
• Dyslipidaemia (high cholesterol) or on cholesterol treatment “statins”
• Obstructive Sleep Apnoea
• Cardiovascular disease
• Type 2 diabetes
If you feel that you meet the criteria in Cohort 1, you will also be required to engage in a weight management support programme which will be commissioned nationally by NHS England to support patients being prescribed Mounjaro. This is a condition of prescribing set by NHS England.